GSK Wins FDA Nod to Target 21M Younger Adults With RSV Vaccine

Edgen Stock·Mar 16 2026, 11:24

Share to

Share to

Copy link

Key Takeaways

The U.S. Food and Drug Administration (FDA) expanded the approval for GSK's Arexvy RSV vaccine to include high-risk adults aged 18-49. This strategic move opens up a market of an estimated 21 million people and places GSK in direct competition with Pfizer's already-approved Abrysvo vaccine in this key demographic.

Expanded FDA Approval: The FDA has approved GSK's Arexvy for adults aged 18-49 at increased risk for severe RSV disease, broadening its previous indication for older adults.
Market Expansion: This decision adds an estimated 21 million potential patients in the U.S. to Arexvy's addressable market, targeting individuals with chronic health conditions.
Intensified Competition: The approval enables GSK to compete directly with Pfizer's Abrysvo, which recorded over $1 billion in 2025 sales after securing approval for the same age group.

FDA Approves Arexvy for 21 Million Younger At-Risk Adults

On March 13, the U.S. Food and Drug Administration (FDA) granted expanded approval for GlaxoSmithKline's (GSK) respiratory syncytial virus (RSV) vaccine, Arexvy. The new indication covers adults aged 18 to 49 who are at increased risk for severe RSV-related illness due to underlying medical conditions. This decision significantly broadens the vaccine's reach beyond its prior approvals for adults aged 50 and older.

The expansion targets an estimated 21 million adults in the United States with pre-existing conditions like asthma, diabetes, or chronic heart disease. This demographic experiences a significant healthcare burden from the virus, accounting for approximately 17,000 hospitalizations and 277,000 emergency department visits annually, underscoring the medical need for preventative treatment.

Approval Puts GSK on Level Footing with Pfizer's $1B Abrysvo

This regulatory milestone is critical for GSK's commercial strategy, as it places Arexvy in direct competition with Pfizer's Abrysvo. Pfizer's vaccine was approved for the same 18+ at-risk population in 2024 and generated over $1 billion in sales in 2025. GSK's Arexvy, which recorded sales of £593 million ($785 million) last year, can now work to reclaim market share lost to its primary rival.

The FDA's decision was supported by data from a Phase IIIb trial which demonstrated that Arexvy generated a non-inferior immune response in the 18-49 age group compared to adults aged 60 and over. While GSK and Pfizer are the main contenders, Moderna’s mResvia also competes in the market but has struggled to gain traction, with its sales falling to just $8 million last year.